respectively, for non-HL during the same period, according to the annual report of the Cancer Registry System (CRS) of the Department of Health, Executive Yuan, Taiwan (http://crs.cph.ntu.edu.tw). It would be of interest to know whether the clinical pattern of HL differs between Taiwanese and Western populations. Here, we report the characteristics of HL in a cohort of 133 patients in a university hospital in Taiwan and compare them with those in Western countries. Our results may shed light on the direction of future studies of HL in Taiwan and other Asian countries.
Methods

Patients
From January 1985 to December 2004, 173 patients with HL, compared with 1975 patients with non-HL in the same period, were registered in the Cancer Registry of the Office of Medical Records, National Taiwan University Hospital. Among them, 24 had received initial therapy elsewhere before being referred to this institute and 16 refused management and were lost to follow-up soon thereafter. The remaining 133 patients were enrolled in this study. The clinical characteristics and laboratory data were collected retrospectively.
HL was categorized histopathologically by the Rye classification system. 6 The disease was staged clinically according to the Ann Arbor system. 7 Bulky tumor was defined as tumor size greater than 10 cm in diameter or widening of the mediastinum by greater than one third of the maximum intrathoracic diameter on a chest radiograph. 7 Twenty-three patients (17%) received COPP chemotherapy (cyclophosphamide instead of mechlorethamine in MOPP, in combination with vincristine, procarbazine and prednisone); 8,9 69 (52%) received ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine); 10 25 (19%) received a combination of ABVD and COPP, BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) or other mixed COPP and ABVD based multidrug combination chemotherapy; 11, 12 and three patients received other chemotherapeutic regimens. Forty-nine patients (37%) were treated with chemotherapy alone, 10 (8%) with radiotherapy only, and 71 (53%) with combined chemotherapy and radiotherapy. Three patients died of comorbidities before any definitive treatment.
Statistical analyses
The χ 2 or Fisher's exact test was used to compare categorical data. Nonparametric analysis was used to compare age distribution. Binomial distribution was used to test the gender distribution in this area from that reported in Western countries. Survival curves were generated using the KaplanMeier method and compared using the log-rank test. Multivariate analyses to clarify the effects of individual factors were performed with Cox regression. All statistical analyses were performed using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows, and p values less than 0.05 were considered significant.
Results
Clinical characteristics
The characteristics of the 133 patients are summarized in Table 1 . The median age was 26 years (range, 3-84 years). Young adults younger than 45 years comprised 77% of patients. 13 The number of female and male patients was nearly equal. The age distribution was similar between males and females, showing a young-adult mode with peak incidence around the age of 20 years. The nodular sclerosis type (NS-HL) was the most common histopathologic subtype (n = 60, 45%), followed by mixed cellularity type (MC-HL, 29%), lymphocyte predominant type (LP-HL, 13%) and lymphocyte depleted type (LD-HL, 2%). About half of patients had localized diseases (stage I and II), and around one third each presented with B symptoms and bulky tumor, respectively. Although the International Prognostic Score (IPS) was initially developed and validated in advanced HL, 13 we tried to apply the score system to the whole cohort for risk stratification. Of the 99 HL patients with adequate data to be rated, more than two thirds had scores ≤ 2. The characteristics were further analyzed according to the histologic types of HL. There were significant differences among the four groups of patients with regard to gender, presentation of bulky tumor or B symptoms, location of primary lesions and IPS (Table 2 ). In contrast to LP-HL, MC-HL and LD-HL, NS-HL occurred more frequently in females than in males. While 43% of patients with NS-HL and 32% of those with MC-HL had bulky tumors, none of the patients with LP-HL did. Most LP-HL and MC-HL patients presented with cervical lymphadenopathy, compared with NS-HL patients in whom involvement of cervical lymph node and mediastinum was almost equal. Patients with LP-HL had a higher frequency of lower IPS score than other patients.
Outcomes
The overall complete remission (CR) rate was 87% and the overall survival (OS) rate at 10 years was 79% after a median follow-up time of 78 months (range, 1-295 months; Figure 1 ). As summarized in Table 3 , the variables that were associated with a higher CR rate included age younger than 45 years, earlier disease stage, absence of B symptoms or marrow involvement, and low IPS. These factors were also associated with higher OS rate at 10 years. In addition, histologic type and gender, although having no significant association with CR rate, was closely associated with OS rate. Female patients and patients with LP-HL and NS-HL had a higher OS rate than male patients and patients with MC-HL, LD-HL and unclassified HL. The OS rate of patients who obtained CR after initial definitive therapy was excellent, but none of the patients who failed to achieve CR after front-line therapy had long-term survival. In the multivariate analysis, the achievement of CR was the only independent factor to be associated with good OS (Table 3, Figure 2 ).
In total, 130 patients received definitive therapy. Treatment outcomes according to treatment modalities are summarized in Table 4 . The choice of modalities (chemotherapy, radiotherapy or chemotherapy plus radiotherapy) was associated with CR and OS rates, but the significance was lost if the analyses were performed separately among groups of different stages. In patients who had received chemotherapy as front-line treatment, ABVD or ABVD-containing regimens were associated with both higher CR and OS rates.
Of the 18 patients who did not achieve CR, including the three who died before any definitive treatment, six had NS-HL, eight had MC-HL, and four had unclassified HL. Two patients were treated with salvage chemotherapy of ESHAP (etoposide, corticosteroid, cytarabine and cisplatin) followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). Two patients were treated with COPP plus radiotherapy and ABVD as salvage chemotherapy, and eight patients died before administration of salvage chemotherapy. However, none of these 12 patients achieved durable remission and survival. Only one patient went into remission after high dose chemotherapy with autologous hematopoietic stem cell transplantation (auto-HSCT). The remaining two patients were lost to follow-up soon thereafter. Among the 115 patients who achieved remission after induction therapy, 21 had disease relapse at the end of the study, with an overall cumulative relapse rate of 23% at 10 years ( Figure 3) . The median time from diagnosis to performed after the achievement of a second CR in nine patients. All these patients had continuous second remission with OS of 40-171 months. Among 94 patients who achieved continuous CR after initial therapy, six had died at the time of writing; four died of causes unrelated to HL (infection in two, coronary heart disease in one and flare up of hepatitis B in one), one died of lung cancer 10 years after HL diagnosis, and one died of cytomegalovirus disease after auto-HSCT. The two patients who had died of coronary heart disease and lung cancer had received radiotherapy at the neck and mediastinum. Another patient had colon cancer 10 years after therapy for HL, but he was alive without HL and colon cancer at his last follow-up.
Discussion
It is known that the incidence of HL is much lower in Asia than in the West. 14 19 These differences between this area and the West might be explained by both racial and environmental differences in the pathogenesis of HL in various geographic areas. 4, 18 Further countrywide epidemiologic studies of HL in Taiwan are warranted to clarify these points.
Aside from these features, the other clinical characteristics of HL in this area are not much different from those in the West, 19 suggesting that after the development of HL, the disease nature and progression are similar among different areas. This is reflected in the treatment results. A high cure rate of patients with HL was demonstrated in this study. Although the choice of treatment modalities (radiotherapy, chemotherapy alone, or in combination) seemed to be associated with outcomes, the association became insignificant after stage stratification because the clinical stage would influence the treatment plans for the patients. On the other hand, induction chemotherapy with ABVD-containing regimen resulted in better outcome than other regimens. This result is compatible with the current concept that ABVD is the first-line chemotherapy regimen for treating HL.
22-25
The standard of salvage therapy for patients with relapsed HL is still controversial, especially the timing of auto-HSCT in relapsed HL. In a large randomized clinical trial, auto-HSCT improved relapse-free survival but failed to improve OS. 26 Conventional salvage chemotherapy, radiotherapy and auto-HSCT were used as salvage therapy in our cohort, and all led to satisfactory results. So the treatment of choice remains to be determined. However, auto-HSCT in our series, although only performed in a limited number of patients, revealed good results without excess of toxicity, suggesting the feasibility, efficacy and tolerability of this treatment. Auto-HSCT should thus be one of the rational options of salvage treatment. However, the outcomes of those who had refractory diseases, either primary or chemoresistant at relapse, were extremely poor. Although successful treatment of HL by allo-HSCT has been reported, 27 no patients in our cohort survived after allo-HSCT, which was comparable to the poor experience with conventional allo-HSCT for HL in the West. 28 Recently, there have been promising preliminary results of reduced-intensity or non-myeloablative allo-HSCT in treating relapsed or refractory HL, which are worthy of further investigation. 29, 30 Another important issue in treating this highly curative disease is the development of secondary malignancies or heart diseases in long-term follow-up. 22, 23, 25, 31 Rare cases, surprisingly, were discovered on chart review that had secondary malignancies or heart diseases. However, due to the rarity of such patients as well as inadequate duration of follow-up, it is too early to make a conclusion at present. The long-term toxic effects of radiotherapy and chemotherapy for HL in Asians remain to be investigated. In our analysis, the relevant factors that were associated with outcomes in HL were similar to those reported previously. 13, 32 Surely, many of these factors are intercorrelated and, due to the small patient number, we are not willing to set a distinct prognostic model by analysis of our cohort. But an interesting finding was that IPS was able to stratify all HL patients, not only those with an advanced stage of the disease. Because the scoring system was initially validated in advanced HL by the International Prognostic Factor Project, 13 its applicability to all patient groups remained unclear. In our analysis, IPS correlated with outcomes in the whole patient group, suggesting its feasibility for generalized usage. This is worthy of further validation by large studies.
